TCRX - TScan Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
2.12 0.13 (5.96%)	---	---	---	---	0.11 (5.09%)	0.0 (0.0%)	0.0 (0.0%)

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Market Period: Closed

Earnings & Ratios

Basic EPS:: -0.28
Diluted EPS:: -0.28
Basic P/E:: -8.0229
Diluted P/E:: -8.0229
RSI(14) 1m:: 100.0
VWAP:: 2.25
RVol:: 0.9838

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	2.21 -0.03 (-1.32%)	Oct 15 12:15
1m	Price decrease 1m	2.19 -0.04 (-1.79%)	Oct 15 11:10
1m	Price increase 1m	2.27 +0.02 (+1.12%)	Oct 15 10:40
1m	Price increase 1m	2.24 +0.03 (+1.36%)	Oct 15 10:08
10m	Price increase 10m	2.24 +0.07 (+3.03%)	Oct 15 10:08